Malaysia
Search
Sign In
Change Password
Points
Sign Out
Rheumatology
Top Medical News
Levels of fibroblast growth factor (FGF)-21, an adipokine linked to metabolic stress, correlate with obesity and inflammatory cytokines, as well as with worsening physical functioning in patients with rheumatoid arthritis (RA), suggests a study.
Among systemic lupus erythematosus (SLE) patients with musculoskeletal symptoms, those who have positive ultrasound appear to show better response to therapy, a study reports.
Engaging in higher levels of physical activity seems to protect against the risk of developing rheumatoid arthritis (RA), although this relationship is not causal, according to a Mendelian randomization analysis.
Secukinumab, at both 300 and 150 mg, scores high in the management of psoriatic arthritis (PsA) patients with axial manifestations and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs), as shown in the results of the phase III MAXIMISE trial.
Among young adults with hypertension, treatment with the urate-lowering drug allopurinol appears to improve endothelial function, although this does not translate to meaningful reductions in blood pressure or inflammation levels, as shown in a study.
Low disease activity (LDA) and remission in women with rheumatoid arthritis (RA) can be easily achieved during pregnancy with the help of a modified treat-to-target (T2T) approach that incorporates the use of tumour necrosis factor inhibitors (TNFIs), as shown in the PreCARA* study.
Special Reports
Conference Reports
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
The IL-1 receptor antagonist anakinra – a drug for rheumatoid arthritis – demonstrated potential in treating gout, as it reduced gout pain and flares to similar degrees as triamcinolone, results of the ANAGO* study have shown.
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.